DC 9476
Alternative Names: DC-9476Latest Information Update: 19 Dec 2024
Price :
$50 *
At a glance
- Originator DeepCure
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action BRD4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hidradenitis suppurativa; Rheumatoid arthritis
Most Recent Events
- 19 Dec 2024 Preclinical trials in Hidradenitis suppurativa in USA (PO) (DeepCure pipeline, December 2024)
- 24 Oct 2024 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis released by DeepCure
- 04 Oct 2024 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis released by DeepCure